期刊文献+

阿托伐他汀与氯吡格雷对ACS患者氯吡格雷羧酸衍生物血浓度与血小板聚集率的影响 被引量:4

Effects of atorvastatin and clopidogrel on clopidogrel carboxylic acid derivatives blood concentration and platelet aggregation rate in patients with acute coronary syndrome
原文传递
导出
摘要 目的:测定急性冠状动脉综合征(ACS)患者氯吡格雷羧酸衍生物血浓度和血小板聚集率,观察阿托伐他汀和氯吡格雷有无相互作用。方法:对照组为25例健康受试者,ACS组为66例ACS患者。均口服阿司匹林100mg/d、氯吡格雷75mg/d、阿托伐他汀20mg/d,5d后暂停阿托伐他汀,继续氯吡格雷和阿司匹林口服4d,分别于第5天、第9天采用液相色谱串联质谱法测量氯吡格雷羧酸衍生物血浓度,流式细胞仪测定血小板聚集率,比较两组差异。结果:对照组第5天和第9天氯吡格雷羧酸衍生物血浓度分别为(5.76±0.87)ng/dl和(5.67±0.88)ng/dl(P=0.351),血小板聚集率分别为(44.25±16.37)%与(47.61±16.67)%(P=0.083)。ACS组第5天和第9天氯吡格雷羧酸衍生物血浓度分别为(5.96±0.87)ng/dl和(5.86±0.97)ng/dl(P=0.115),血小板聚集率分别为(47.70±15.07)%与(47.02±15.45)%(P=0.622)。相关性分析显示,血氯吡格雷羧酸衍生物浓度和血小板聚集率呈正相关。结论:氯吡格雷羧酸衍生物血浓度和血小板聚集率相关性良好,氯吡格雷和阿托伐他汀未见相互作用。 Objective:To investigate the effects of atorvastatin and clopidogrel on carboxylic acid derivatives blood concentration and rate of platelet aggregation in patients with acute coronary syndrome(ACS).Method:The control group included 25healthy subjects,ACS group included 66ACS patients.All subjects took aspirin 100 mg/d,clopidogrel 75mg/d,and atorvastatin 20mg/d.Five days later,atorvastatin was stopped,while clopidogrel and aspirin orally continued four days.At fifth day and ninth day,we measured clopidogrel carboxylic acid derivatives blood concentration by high performance liquid chromatography coupled with tandem mass spectrometry(HPLC-MS/MS),and tested platele aggregation rate by flow cytometry.Result:At fifth and ninth day,clopidogrel carboxylic acid derivatives blood concentrations were(5.76±0.87)ng/dl and(5.67±0.88)ng/dl(P= 0.351),platelet aggregation rates were(44.25±16.37)% and(47.61±16.67)%(P=0.083)respectively in control group;while(5.96±0.87)ng/dl and(5.86±0.97)ng/dl(P=0.115),(47.70±15.07)%and(47.02± 15.45)%respectively in ACS group(P=0.622).Correlation analysis showed that the derivative concentration of blood clopidogrel carboxylic acid and platelet aggregation rate had positive correlation.Conclusion:Blood levels of clopidogrel carboxylic acid derivative and platelet aggregation have strong and positive correlation.There is no interaction between atorvastatin and clopidogrel.
出处 《临床心血管病杂志》 CAS CSCD 北大核心 2014年第5期412-415,共4页 Journal of Clinical Cardiology
基金 甘肃省卫生行业科研计划项目(No:GSWST 2010-21)
关键词 急性冠状动脉综合征 阿托伐他汀 氯吡格雷 氯吡格雷羧酸衍生物 血小板聚集率 acute coronary syndrome atorvastatin clopidogrel clopidogrel carboxylic acid derivative plate-let aggregation
  • 相关文献

参考文献13

  • 1王燕慧,张灏.他汀类药物与氯吡格雷相互作用争议的现状[J].国际心血管病杂志,2011,38(2):104-107. 被引量:20
  • 2LAU W C, WASKELL L A, WATKINS P B. Ator- vastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction[J]. Circulation, 2003,107 : 32- 37.
  • 3BROPHY J M, BABAPULLE M N, COSTA V, et al. A pharmacoepidemiology study of the interaction between atorvastatin and clopidogrel after percutane-ous coronary intervention [J]. Am Heart J, 2006, 152:263-269.
  • 4SEREBRUANY V L, STEINHUBL S R, HENNEK- ENS C H. Are antiplatelet effects of clopidogrel inhibited by atorvastatin? A research question formulated but not yet adequately tested[J]. Circulation, 2003,107 : 1568 - 1569.
  • 5SAW J, BRENNAN D M, STEINHUBL S R, et al. Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial[J]. J Am Coll Cardiol, 2007, 50:291-295.
  • 6SAW J, STEINHUBL S R, BERGER P B, et al. Lack of adverse clopidogrel-atorvastatin clinical inter- action from secondary analysis of a randomized, pla- cebo-controlled clopidogrel trial [J]. Circulation, 2003,108:921-924.
  • 7WIENBERGEN H, GITT A K, SCHIELE R, et al. Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies[J]. Am J Cardiol, 2003,92 : 285- 288.
  • 8LIM M J, SPENCER F A, GORE J M, et al. Impact of combined pharmacologic treatment with clopidogrel and a statin on outcomes of patients with non-ST-seg- ment elevation acute coronary syndromes: perspec- tives from a large multinational registry [J]. Eur Heart J,2005,26 : 1063- 1069.
  • 9SAW J, BRENNAN D M, STEINHUBL S R, et al. Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial[J]. J Am Coll Cardiol, 2007, 50:291-295.
  • 10MUKHERJEE D, KLINE-ROGERS E, FANG J, et al. Lack of clopidogrel-CYP3A4 statin interaction in patients with acute coronary syndrome [J]. Heart, 2005,91:23-26.

二级参考文献52

  • 1任艺虹,盖鲁粤,杨庭树,王洪叶,王禹,邢攸红,林琳,刘春雪.改良血栓弹力图法和流式细胞测定技术对血小板活性抑制程度的比较研究[J].中华心血管病杂志,2007,35(4):366-367. 被引量:37
  • 2Porto I, Van Gaal W, Banning A. Impact of the elevation of biochemical markers of myocardial damage on long term mortality after percutaneous coronary intervention: results of theCK MBand PCI study[J]. Eur Heart J, 2005,26(20): 2206-2207.
  • 3Briguori C, Visconti G, Focaccio A, et al. Novel approaches for preventing or limiting events (Naples) II trial: impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction[J]. J Am Coll Cardiol, 2009,54 (23) : 2157-2163.
  • 4Patti G, Pasceri V, Colonna G, et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early pereutaneous coronary intervention: results of the ARMYDA ACS randomized trial [J]. J Am Coll Cardiol, 2007,49(12) :1272- 1278.
  • 5Di Sciascio G, Patti G, Pasceri V, et al. Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention : results of the ARMYDA RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial [J]. J AmCollCardiol, 2009,54(6):558 -565.
  • 6Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives[J]. J Am Coll Cardiol, 2007,49(14) :1505 -1516.
  • 7Marian AJ. Cytochrome p-450 polymorphisms and response to clopidogrel[J]. Curr Atheroscler Rep, 2009,11(3):157-160.
  • 8Neubauer H, Gtinesdogan B, Hanefeld C, et al. Lipophilic statins interfere with the inhibitory effects of elopidogrel on platelet function-a flow cytometry study[J]. Eur Heart J, 2003,24(19) : 1744-1749.
  • 9Brophy JM, Babapulle MN, Costa V, et al. A pharmacoe pidemiology study of the interaction between atorvastatin and clopidogrel after percutaneous coronary intervention[J]. Am Heart J, 2006,152(2) :263 -269.
  • 10Saw J, Brennan DM, Steinhubl SR,et al. Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial[J]. J Am Coll Cardiol, 2007,50(4):291-295.

共引文献27

同被引文献40

引证文献4

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部